Cochlear Share Price Drops 12% After FDA Delays Hearing Implant Approval
Cochlear Share Price Drops 12% After FDA Delays Hearing Implant Approval...
Cochlear Limited's (ASX: COH) shares plummeted 12% in early trading Thursday after the U.S. Food and Drug Administration (FDA) postponed its decision on approving the company's next-generation hearing implant. The delay sent shockwaves through the medical device sector and alarmed investors who had anticipated a 2026 rollout for the Nucleus 8 system.
The FDA cited "additional data requirements" in its announcement late Wednesday, pushing the review timeline into late Q3 2026. This marks the second regulatory setback for the Australian hearing technology leader in 18 months. Cochlear's U.S. operations account for 42% of its global revenue, making FDA approvals critical for growth.
Analysts at Morgan Stanley downgraded Cochlear from 'Overweight' to 'Equal-weight' following the news, slashing their price target by 15%. "The delay creates a competitive window for rivals like Med-El and Advanced Bionics," noted healthcare analyst David Chen. Retail investors flooded social media platforms Thursday morning, with many expressing concerns about the company's short-term outlook.
The sell-off erased nearly $2.5 billion from Cochlear's market capitalization by 10:30 AM EST. The stock's plunge triggered a broader decline in the S&P/ASX 200 Health Care index, which fell 1.8% in Sydney trading. Cochlear last traded at $189.50 AUD, its lowest level since November 2025.
Patient advocacy groups reacted with disappointment, as the Nucleus 8 system promises improved speech recognition in noisy environments. The American Speech-Language-Hearing Association had previously endorsed the technology's potential benefits for children with profound hearing loss. An FDA spokesperson confirmed the review extension doesn't indicate safety concerns but requires additional clinical data analysis.
Cochlear CEO Dig Howitt stated the company is "working closely with the FDA to address all questions" during a hastily arranged investor call. The delay comes as Congress debates tighter medical device regulations, adding uncertainty to the sector. Trading volume for Cochlear shares tripled its 30-day average by midday Thursday.
Market observers note the sell-off may present a buying opportunity if the FDA ultimately approves the device. Cochlear maintains strong fundamentals with 17% revenue growth in FY2025. The company expects to provide an updated regulatory timeline during its half-year earnings report on May 15.
